Effects of double dose alpha 1 antitrypsin (AAT) therapy on cytokine pathways in AAT Deficiency (AATD)
M. Campos (Miami, United States of America), P. Geraghty (New York, United States of America), G. Holt (Miami, United States of America), E. Donna (Miami, United States of America), E. Mendes (Miami, United States of America), L. Escobar (Miami, United States of America), L. Luna (Miami, United States of America), R. Stockley (Birmingham, United Kingdom)
Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond
Session: COPD phenotypes: a1 antitrypsin deficiency and beyond
Session type: Poster Discussion
Number: 571
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Campos (Miami, United States of America), P. Geraghty (New York, United States of America), G. Holt (Miami, United States of America), E. Donna (Miami, United States of America), E. Mendes (Miami, United States of America), L. Escobar (Miami, United States of America), L. Luna (Miami, United States of America), R. Stockley (Birmingham, United Kingdom). Effects of double dose alpha 1 antitrypsin (AAT) therapy on cytokine pathways in AAT Deficiency (AATD). 571
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: